Isaac Health Raises $5.7 Million To Redefine The Future Of Brain Healthcare
Isaac Health – a digital health company emerging as a national leader in brain health – announced the successful completion of its oversubscribed $5.7 million seed round. The funding round was led by Meridian Street Capital and B Capital, with participation from Primetime Partners, Co-Found Partners, VU Venture Partners, and AirAngels.
A large percentage of mild cognitive impairment goes undiagnosed. And the need for specialist care is exacerbated by the FDA’s recent approval of a disease-modifying therapy for early-stage Alzheimer’s disease, which requires specialist evaluation and follow-up.
So Isaac Health is redefining the future of brain healthcare by utilizing cutting-edge technology and predictive machine learning to identify patients with different cognitive and brain health conditions and enable center-of-excellence-level care to be scaled across communities.
Isaac Health works with health systems and health plans to screen, diagnose, treat, and manage their populations who have brain health conditions, starting with dementia. And this strategic funding empowers Isaac Health to develop further and expand its innovative brain health provider platform, driving advancements in the screening, diagnosis, treatment, and management of brain health and dementia. This funding round is instrumental in scaling operations and driving strategic partnerships to position Isaac Health as a leader in the rapidly evolving brain health landscape.
KEY QUOTES:
“We are thrilled to have secured this significant investment, which reflects the confidence our investors have in the potential for Isaac Health to be the category-defining player for brain health. This funding will enable us to accelerate our mission of providing high-quality patient-centered care for the evaluation and management of dementia and many other brain health conditions.”
— Julius Bruch, CEO of Isaac Health
“We are currently at a historic inflection point for brain health with the first full FDA-approved disease modifying treatment for early-stage Alzheimer’s disease, and the company’s commitment to innovation, coupled with the vast potential size of the brain health market, strongly aligns with our vision for the future of healthcare. We look forward to collaborating with Isaac Health as they continue to make significant strides in transforming patient care.”
— Karen Page, General Partner at B Capital
“Brain health should mean more than just supporting the late stages of disease. It should mean early detection and proactive care, in and beyond the four walls of a clinic. Isaac Health, through their novel model and technology, has the potential to scale the gold-standard of care. We are excited to partner with Isaac Health as they play a real role in reducing the burden of dementia and other brain conditions on individuals and their families.”
— George Ribaroff, Partner at Meridian Street Capital
link